Marriott Marquis San Diego,
Live In-Person Event: December 15 - 18, 2024
Antibody Drug Conjugate Insights
Access speaker interviews, sponsored content, and expert opinion pieces that provide actionable insights into the latest advancements in antibody-drug conjugates, including the transformative role of AI and machine learning in accelerating discovery and development. Stay informed with valuable event resources and explore key trends shaping the future of targeted ADC therapies and innovative computational approaches.
Antibody Drug Conjugates Content
David Baker: Designing Life’s Building Blocks with AI-Powered Protein Engineering
This interview with David Baker, a computational biologist and 2024 Nobel Prize winner in Chemistry, explores his ground breaking work in computational protein design. As a professor of biochemistry at the University of Washington, Baker has pioneered tools for creating synthetic proteins from scratch, revolutionizing fields like medicine, materials science, and environmental solutions. In the discussion, he highlights the transformative role of AI systems like AlphaFold in enabling precise protein engineering to address global challenges, including pollution and food security.
Jerome Boyd-Kirkup: Pioneering Dual-Payload Antibody-Drug Conjugates
Jerome Boyd-Kirkup is the Chief Scientific Officer and co-founder of Hummingbird Bioscience. He leads groundbreaking work in precision biotherapeutics, focusing on dual-payload antibody-drug conjugates (ADCs) to overcome resistance in cancer treatments. Jerome discusses the inspiration behind developing dual-payload ADCs, which aim to address resistance seen with earlier single-payload ADCs.
Marika Nestor: The Future of Radioimmunotherapy
Marika Nestor, a leading figure in Biomedical Radiation Sciences at Uppsala University, discusses her groundbreaking work in radioimmunotherapy (RIT), a cutting-edge approach to cancer treatment that combines the precision of radiolabeled antibodies with the power of radiotherapy. With a focus on developing innovative radiopharmaceuticals and radiosensitizers, her team has achieved significant milestones, including a novel radiolabeled antibody now entering Phase 1 clinical trials. Nestor shares insights into the promise of RIT for addressing metastatic cancer, the challenges of optimizing tumor targeting, and the exciting potential of combination therapies and emerging technologies to revolutionize cancer care.
Brian Fiske: Innovating Antibody-Drug Conjugates
Brian Fiske, co-founder of Mythic Therapeutics, delves into the challenges and breakthroughs in the development of antibody-drug conjugates (ADCs). He explains how Mythic’s proprietary FateControl technology enhances ADC uptake, enabling targeted therapies to address previously unmet medical needs. Brian shares insights into the design and early clinical success of MYTX-011, an ADC with a pH-sensitive mechanism targeting cMET expression, which promises improved safety and efficacy compared to traditional ADCs.
Meet the experts leading Antibody Drug Conjugate Innovation
15+
FDA Approved ADC's
>90%
Target Specificity
$12B+
Market Size by 2026
40,000+
Patients treated
10+ years
of research and development
10-100x
potency compared to traditional chemotherapy
Exploring Antibody Drug Conjugates: Key Topics at Our Upcoming Event
How does MYTX-011 broaden the potential patient base for ADC therapies targeting cMET?
MYTX-011, an investigational ADC, enhances anti-tumor activity across patients with a wider spectrum of cMET expression levels, including those with lower to moderate expression. This ADC promotes better internalization and cytotoxicity with an extended pharmacokinetic profile and a reduced side-effect profile, showing robust activity in preclinical models. Brian Fiske, Ph.D., will be discussing the development of MYTX-011, an investigational ADC targeting cMET with enhanced activity against tumors expressing low to moderate levels of this receptor.
What role does chain exchange technology play in ADC development?
Chain exchange enables the development of ADC matrices by varying binders, formats, attachment positions, and payloads. This flexibility helps in optimizing ADC function, revealing that format selection can significantly impact efficacy and specificity, similar to bispecific antibodies. Ulrich Brinkmann, will be exploring how chain exchange technology is advancing ADC development by enabling the creation of matrices combining various binders, payloads, and formats.
How can a dual-payload ADC platform overcome drug resistance in HER2+ cancers?
Dual-payload ADCs like those developed by Hummingbird Bioscience combat resistance by deploying two cytotoxic agents in a single molecule, targeting cancer cells more effectively, even in resistant models. This approach enhances the therapeutic window while maintaining tolerability. Jerome Boyd-Kirkup, Ph.D., will be presenting Hummingbird Bioscience's dual-payload ADC platform, which addresses payload resistance, a common challenge in cancer therapies.
What is the CAPAC platform, and how does it enhance ADC targeting?
The CAPAC platform selectively activates ADC payloads at the tumor site, reducing systemic toxicity. This innovation represents a significant advance for ADCs by enhancing therapeutic index and improving patient safety profiles. José M. Mejía Oneto, M.D., Ph.D., will be talking on the CAPAC (Click Activated Protodrugs Against Cancer) platform, which activates ADCs at the tumor site using click chemistry.
What potentiation strategies are being explored to improve radioimmunotherapy efficacy?
Research into radioimmunotherapy potentiation includes strategies such as combination therapies and antibody modifications to improve efficacy and reduce toxicity. These enhancements aim to address the challenges of radioimmunotherapy, such as prolonged radioactivity exposure. Marika Nestor, Ph.D., will be examining potentiation strategies for radioimmunotherapy (RIT), including antibody modifications and combination therapies.
How can FcγR-ablated TLR7 agonist ADCs reduce immune side effects?
FcγR-ablated TLR7 agonist ADCs avoid FcγR binding to reduce off-target immune activation. This approach maintains effective tumor-specific immune activation while reducing immune-related side effects, with promising results in breast and pancreatic cancer models. Anqi Zhang, Ph.D. will be discussing the development of FcγR-ablated TLR7 agonist ADCs, which minimize immune side effects by bypassing Fcγ receptor interactions.
